Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast add-on to fixed LABA/ICS in severe COPD
NL-OMON38122Phase 4Active, not recruiting
- Sponsor
- Takeda
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Roflumilast add-on with Placebo add-on (2 arms). Primary endpoint: Rate of moderate or severe COPD exacerbations per patient per year. Started Nov 2011; status: active, not recruiting.
02
Drugs
roflumilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON38122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38122.